Cellular Biomedicine Group to Present a Keynote Address at CAR-TCR Summit Asia
June 21 2018 - 6:30AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in the
development of immunotherapies for cancer and stem cell therapies
for degenerative diseases, will participate in the upcoming CAR-TCR
Summit Asia to be held in Singapore, June 27-28, 2018. The
Company’s CEO, Tony (Bizuo) Liu, will present a keynote address
entitled “Digital Decades Ahead For Biotech” as part of the
“Manufacturing Scale Up & Automation” portion of the Summit.
The Summit hosts key opinion leaders in CAR-TCR development as they
build their development strategy to bring safe and effective CAR-T
and TCR therapies to patients globally.
Presentation: |
|
|
|
|
Digital Decades Ahead
For Biotech |
Speaker: |
|
|
|
|
Tony (Bizuo) Liu,
CEO |
Location: |
|
|
|
|
Four Points By
Sheraton, 382 Havelock Road, Singapore |
Date: |
|
|
|
|
Thursday, June 28,
2018 |
Time: |
|
|
|
|
12:40-1:10pm (SGT) |
About Cellular Biomedicine
GroupCellular Biomedicine Group, Inc. (NASDAQ:CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using products from our integrated GMP
laboratory. Our GMP facilities in China, consisting of twelve
independent cell production lines, are designed and managed
according to both China and U.S. GMP standards. Our Shanghai
facility includes a ”Joint Laboratory of Cell Therapy” with GE
Healthcare and a “Joint Cell Therapy Technology Innovation and
Application Center” with Thermo Fisher Scientific, which
partnerships focus on improving manufacturing processes for cell
therapies. CBMG currently has ongoing CAR-T Phase I clinical trials
in China; CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and
Non-Hodgkin Lymphoma (NHL) and CALL-1 for adult Acute Lymphoblastic
Leukemia (ALL), utilizing CBMG’s proprietary and optimized CD19
construct, a Phase IIb trial in China for Rejoin® autologous Human
Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the
treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial
in China for AlloJoin™ (CBMG’s “Off-the-Shelf” haMPC) for the
treatment of KOA. CBMG is included in the Loncar China BioPharma
index. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements Statements in this
press release relating to plans, strategies, trends, specific
activities or investments, and other statements that are not
descriptions of historical facts and may be forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking information is inherently subject to risks
and uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include those regarding our ability to implement our plans,
strategies and objectives for future operations, including our plan
to configure part of our Shanghai facility with GE Healthcare’s
FlexFactory platform, our ability to execute on proposed new
products, services or development thereof, results of our clinical
research and development, regulatory infrastructure governing cell
therapy and cellular biopharmaceuticals, our ability to enter into
agreements with any necessary manufacturing, marketing and/or
distribution partners for purposes of commercialization, our
ability to seek intellectual property rights for our product
candidates, competition in the industry in which we operate,
overall market conditions, any statements or assumptions underlying
any of the foregoing and other risks detailed from time to time in
CBMG’s reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as “may,” “will,” “expects,” “plans,”
“intends,” “estimates,” “potential,” or “continue,” or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts: Sarah Kelly Director of
Corporate Communications, CBMG+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2024 to May 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From May 2023 to May 2024